USPTO serial 79460512
NORDICCPA9
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- —
What this means
Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.
Need help with NORDICCPA9?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic biomarker reagents for medical purposes; diagnostic reagents for biomarkers for veterinary use; cord blood for medical purposes; umbilical cords for clinical use; placentas for medicinal use; placentas for clinical use; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; diagnostic kits consisting of medical and veterinary diagnostic reagents and assays for use in connection with disease tracing, disease analysis and the quantification of disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; diagnostics for veterinary purposes; diagnostic reagents for veterinary use; diagnostic agents for veterinary use; clinical diagnostic reagents; diagnostic agents and diagnostic materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic preparations for medical or veterinary purposes. | ACTIVE | — |
| 042 | Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; design and development of the following goods: diagnostic biomarker reagents for medical, veterinary and pharmaceutical purposes and for scientific purposes; design and development of the following goods: biochemical and pharmaceutical assays and medical samples; design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to the following fields: clinical trials; veterinary trials; medical experiments; analysis of pharmacodynamic data; analysis of data in connection with the following fields: biomarkers; development of the following goods: diagnostic preparations for medical and veterinary purposes; diagnostic equipment and diagnostic tests; clinical testing services; diagnostic testing services; testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratories; medical, pre-clinical, clinical, biological, biotechnological, veterinary and pharmaceutical research, the conducting of experiments, development and analysis; information, advice and assistance relating to the aforementioned services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 20, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |